MBX-8025
MBX-8025
MBX-8025 (pronunciation: M-B-X-eight-zero-two-five) is a novel peroxisome proliferator-activated receptor (PPAR) delta agonist developed by CymaBay Therapeutics for the treatment of dyslipidemia and other metabolic disorders.
Etymology
The term "MBX-8025" is a proprietary name given by the developing company, CymaBay Therapeutics. The "MBX" prefix is common to all drugs developed by this company, while "8025" is a unique identifier for this specific drug.
Mechanism of Action
MBX-8025 works by activating the PPAR delta receptors, which are involved in the regulation of lipid metabolism and glucose homeostasis. By activating these receptors, MBX-8025 can help to lower levels of low-density lipoprotein cholesterol (LDL-C) and increase levels of high-density lipoprotein cholesterol (HDL-C), thereby improving the overall lipid profile.
Clinical Trials
MBX-8025 has undergone several clinical trials to evaluate its safety and efficacy in patients with dyslipidemia and other metabolic disorders. Results from these trials have shown that MBX-8025 can significantly reduce levels of LDL-C and increase levels of HDL-C, with a favorable safety profile.
Related Terms
- Peroxisome proliferator-activated receptor
- Dyslipidemia
- Lipid metabolism
- Glucose homeostasis
- Low-density lipoprotein cholesterol
- High-density lipoprotein cholesterol
- Clinical trials
External links
- Medical encyclopedia article on MBX-8025
- Wikipedia's article - MBX-8025
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski